logo.jpg
Trading Statement - Third Quarter 2005
October 27, 2005 01:58 ET | Ahold Delhaize
Amsterdam, The Netherlands, October 27, 2005 - Ahold today announced consolidated net sales (excluding VAT) of EUR 10.2 billion for the third quarter of 2005 (12 weeks: July 18, 2005 - October 9,...
MorphoSys Reports Nine Months 2005 Results
October 27, 2005 01:42 ET | MorphoSys AG
MARTINSRIED, Germany, Oct. 27, 2005 (PRIMEZONE) -- MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) today reported financial results according to IFRS for the first nine months ended...
MorphoSys Appoints Dr. Marlies Sproll as Chief Scientific Officer and Member of the Management Board
October 27, 2005 01:37 ET | MorphoSys AG
MARTINSRIED, Germany, Oct. 27, 2005 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) today announced the appointment of Dr. Marlies Sproll (47) as Chief Scientific Officer...
NOVARTIS logo.jpg
Xolair® granted marketing authorization in Europe as novel therapy for severe allergic asthma
October 27, 2005 01:30 ET | Novartis Pharma AG
Xolair provides asthma patients with one of the most significant advances in last 15 years  The first monoclonal antibody approved for the treatment of asthma in Europe Basel, October 27,...
NOVARTIS logo.jpg
Xolair®, traitement novateur de l'asthme allergique sévère, obtient l'autorisation de mise sur le marché pour l'Union européenne
October 27, 2005 01:30 ET | Novartis Pharma AG
Xolair constitue l'une des avancées les plus significatives de ces 15 dernières années pour les patients asthmatiques.  Xolair est le premier anticorps monoclonal à recevoir une homologation...
NOVARTIS logo.jpg
Xolair® wird in Europa als neuartige Therapieoption gegen schweres allergisches Asthma zugelassen
October 27, 2005 01:30 ET | Novartis Pharma AG
Xolair stellt für Asthmapatienten einen der  bedeutendsten Behandlungsfortschritte seit 15 Jahren dar  Xolair ist der erste monoklonale Antikörper, der in Europa zur Behandlung von...
Private Equity Holding: Halbjahresabschluss per 30. September 2005
October 27, 2005 01:00 ET | Private Equity Holding AG
Der Fair Value pro Aktie betrug am 30. September 2005 EUR 29.36 (31. März 2005: EUR 31.11).     Das Anlagevermögen beläuft sich auf EUR 117.3 Mio. (31. März 2005: 135.4 Mio.). Die...
Private Equity Holding: Half-Year Results as of September 30, 2005
October 27, 2005 01:00 ET | Private Equity Holding AG
The fair value per share of Private Equity Holding stood at EUR 29.36 as of September 30, 2005 (March 31, 2005: EUR 31.11).     Long-term assets totaled EUR 117.3 million (March 31, 2005:...
Private Equity Holding: Halbjahresabschluss per 30. September 2005
October 27, 2005 01:00 ET | Private Equity Holding AG
Der Fair Value pro Aktie betrug am 30. September 2005 EUR 29.36 (31. März 2005: EUR 31.11).     Das Anlagevermögen beläuft sich auf EUR 117.3 Mio. (31. März 2005: 135.4 Mio.). Die...
Private Equity Holding: Half-Year Results as of September 30, 2005
October 27, 2005 01:00 ET | Private Equity Holding AG
The fair value per share of Private Equity Holding stood at EUR 29.36 as of September 30, 2005 (March 31, 2005: EUR 31.11).     Long-term assets totaled EUR 117.3 million (March 31, 2005:...